Financial Data and Key Metrics Changes - Barrick reported record operating cash flow, free cash flow, and adjusted net earnings for Q3 2025, with free cash flow increasing by 274% quarter-over-quarter [10][11] - The company ended the quarter with a net cash position, allowing for a 25% increase in the base dividend and a significant share repurchase program totaling $598 million [10][11] - Attributable EBITDA increased by 20% quarter-over-quarter, driven by higher gold prices and production volume growth [10][11] Business Line Data and Key Metrics Changes - Gold production increased by 4% from Q2, with notable contributions from Kibali, Cortez, and Turquoise Ridge [8][13] - Copper production slightly declined due to a planned shutdown at Lumwana, but is expected to meet annual guidance [8][16] - North America's attributable EBITDA rose by 19% from Q2, with all sites reporting lower unit costs per ounce [13] Market Data and Key Metrics Changes - The gold price experienced a 5% increase, contributing to a 25% quarter-on-quarter increase in attributable gold EBITDA [8] - The company anticipates continued growth in both gold and copper production in Q4, aligning with its 2025 production guidance [9][17] Company Strategy and Development Direction - The company is focusing on enhancing operational performance and safety, particularly in its North American gold assets [4][5] - Barrick is prioritizing the Fourmile project, which is considered one of the most significant gold discoveries of the century, with plans to double the existing resource [14][19] - The company aims to maintain a strong balance sheet while investing in growth and returning excess cash to shareholders [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of safety and operational performance, especially following three fatalities in the quarter [6][7] - The operational review aims to stabilize and improve consistency in production, with no major changes expected in medium-term guidance [31][32] - The company is optimistic about achieving its production guidance for both gold and copper, despite the challenges faced [17] Other Important Information - The company has increased its exploration budget for Fourmile by over $10 million for the remainder of 2025 [14] - Asset sales, including Hemlo and Tongon, are expected to close before the end of the year, further strengthening the company's financial position [11] Q&A Session Summary Question: Can you provide a framework for the operational review at Nevada Gold Mines? - The operational review focuses on stabilizing operations and improving maintenance approaches to avoid unexpected downtimes [22][23] Question: Is there any update on the maintenance issues at Carlin? - The scaling issue at Gold Quarry occurred post-maintenance shutdown and has been addressed [24][25] Question: What is the expected output of the operational review? - The review aims to provide more predictable outcomes and will inform next year's budget, but no major changes are anticipated [30][31] Question: Are there any other potential areas for asset sales? - Currently, the focus remains on North America and key growth projects, with no immediate plans for additional asset sales [39] Question: What changes in corporate policies can be expected under the new leadership? - The strategy remains consistent, with an increased focus on North America and Nevada as key growth areas [81]

Financial Data and Key Metrics Changes - Barrick reported record operating cash flow, free cash flow, and adjusted net earnings for Q3 2025, with free cash flow increasing by 274% quarter-over-quarter [10][11] - The company ended the quarter with a net cash position, allowing for a 25% increase in the base dividend and a significant share repurchase program totaling $598 million [10][11] - Attributable EBITDA increased by 20% quarter-over-quarter, driven by higher gold prices and production volume growth [10][11] Business Line Data and Key Metrics Changes - Gold production increased by 4% from Q2 2025, with notable contributions from Kibali, Cortez, and Pueblo Viejo [8][13] - Copper production slightly declined due to a planned shutdown at Lumwana, but is expected to meet annual guidance [8][16] - North America's attributable EBITDA rose by 19% from Q2, with all sites reporting lower unit costs per ounce [13] Market Data and Key Metrics Changes - The gold price experienced a 5% increase, contributing to higher margins and cash flow [10][11] - The company anticipates continued growth in gold production for Q4, aligning with its 2025 production plan [8][17] Company Strategy and Development Direction - The company is focusing on enhancing operational performance and safety, particularly in its North American gold assets [4][5] - Barrick is prioritizing the Fourmile project, which is considered one of the most significant gold discoveries of the century, with plans to double the existing resource [14][15] - The strategic focus is on North America, with an emphasis on Nevada as a core asset for future growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the strong operational and financial results but emphasized the need for improved safety measures following three fatalities [5][6][7] - The operational review aims to stabilize performance and ensure consistent delivery, with no major changes expected in medium-term guidance [31][32] - The company is committed to maintaining a strong balance sheet while returning excess cash to shareholders [11][12] Other Important Information - The company is conducting a full investigation into recent fatalities to enhance safety protocols [6][7] - Asset sales, including Hemlo and Tongon, are expected to close before year-end, contributing to cash flow [11][17] Q&A Session Summary Question: Can you provide a framework for the operational review at Nevada Gold Mines? - The review aims to stabilize operations and improve maintenance approaches to avoid unexpected downtimes [22][23] Question: Is there any update on the maintenance issues at Carlin? - The scaling issue at Gold Quarry occurred post-maintenance and has been addressed [24][25] Question: What is the expected output of the operational review? - The review will inform next year's budget but is not expected to lead to major changes in guidance [30][31] Question: Are there any other potential asset sales in the portfolio? - Currently, the focus is on North America and key growth projects, with no other asset sales being considered at this time [39] Question: What changes in corporate policies can be expected under the new leadership? - The strategy remains consistent, with a heightened focus on North America and Nevada for growth opportunities [81]

Financial Data and Key Metrics Changes - Total company revenue for Q3 2025 was approximately $51 million, representing an 11% decline on a same-station basis and a 7.5% decline year-over-year, excluding $2.7 million of political revenue from Q3 2024 [4][12] - Digital revenue accounted for roughly 25% of total company revenue, up from 19% a year ago, with a same-station growth of approximately 28% year-over-year [6][16] - Digital operating margin expanded from roughly 7% in the prior year period to 21% in Q3 2025, reflecting improved monetization efficiency [16] Business Line Data and Key Metrics Changes - AudioPlus revenue exceeded $1.2 million in Q3, representing over 200% growth from Q2, driven by strong performance in Philadelphia, Detroit, and Boston [7] - Local direct revenue, which includes digital packages sold locally, grew 3.5% year-over-year, now representing nearly 60% of total local business [9] - National agency revenue declined approximately 16% year-over-year, while local agency revenue fell roughly 17%, showing improvement from previous quarters [12][14] Market Data and Key Metrics Changes - Healthcare now accounts for nearly 9% of total revenue, up from 6% a year ago, indicating growth in this category [15] - Entertainment revenue declined nearly 40% year-over-year, reflecting a softer event calendar and delayed commitments from national promoters [15] - Retail revenue decreased 22% year-over-year as advertisers shifted spending toward e-commerce and digital performance platforms [15] Company Strategy and Development Direction - The company aims to scale higher margin digital products, strengthen the quality of earnings, and pivot the sales organization toward direct data-driven relationships [4][24] - A self-serve advertising portal was piloted in Q3, aimed at enabling small and mid-sized businesses to independently plan and purchase digital campaigns [8][9] - The company is focused on efficiency and expense control, with a comprehensive cost reduction plan expected to yield an additional $1.5 million in run rate savings by year-end [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with revenue performance, viewing results as unacceptable, and emphasized the need for aggressive execution across the sales organization [5][24] - Despite industry headwinds, there is optimism regarding local direct and O&O product growth, with expectations for total company revenue in Q4 pacing down roughly 20% year-over-year [24] - The company anticipates full-year 2025 station operating and corporate expenses to be down between $25 million and $30 million, excluding severance and one-time expenses [24] Other Important Information - The company experienced a leadership change with the resignation of the Chief Financial Officer, and the CEO is now serving as the principal financial officer [3] - The company maintains a cash position of $14.3 million, with capital expenditures totaling approximately $2.2 million in Q3 [19][20] - The company acknowledged the passing of a significant figure in its history, Pierre Robert, highlighting the impact on its culture and community [21][22] Q&A Session Summary Question: Can you comment further on the agency channel issue? At what point did the anniversary? The challenge is there - Management noted that agency business continues to be a headwind but sees slight improvement in Q4 ex-political, with the anniversary of these challenges expected in Q1 next year [25][26] Question: Given the current revenue challenges, do you expect to do more cost savings in 2026? - Management anticipates savings from Q3 and Q4 cuts to be about $4 million for next year, with further savings being explored for 2026 [27][28] Question: Can you provide a sales price on Fort Myers? Who is the buyer of Fort Myers? Do you see the opportunity for more asset sales? - The Fort Myers sale consists of two transactions totaling $18 million, with the buyers being Fort Myers Broadcasting and Sun Broadcasting. The company remains open to discussing creative transactions to reduce debt and leverage [29]

Summary of ProMIS Neurosciences FY Conference Call Company Overview - ProMIS Neurosciences is a publicly listed company on NASDAQ under the ticker PMN, focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease [2][3] - The company is conducting a landmark 100-patient study with its lead monoclonal antibody, PMN310, targeting Alzheimer's disease [2][3] Core Points and Arguments Alzheimer's Disease Study - ProMIS is in the midst of a phase 1b study for Alzheimer's, with over 90% enrollment and data expected soon [3][26] - The study involves administering the drug over 12 months, with an interim analysis planned for mid-next year and final results expected by the end of next year [3][26] Unique Mechanism of Action - PMN310 selectively targets toxic oligomer forms of amyloid beta, which are believed to drive disease progression, rather than the plaque forms that previous therapies have targeted [4][5][7] - The company claims to be the only one with an antibody that selectively targets these toxic oligomers without binding to non-harmful forms [7][10] Differentiation from Competitors - ProMIS utilizes AI and advanced design techniques to create antibodies that specifically target misfolded proteins, a method that differs from competitors who have struggled with cross-reactivity to non-target forms [8][9][10] - Previous therapies targeting plaque have shown limited efficacy and significant side effects, such as ARIA (Amyloid-related imaging abnormalities) [6][12][15] Study Design and Expectations - The phase 1b study is designed to provide definitive answers regarding the drug's efficacy, with a focus on biomarkers, safety, and clinical signals [20][21] - The study aims to enroll 128 patients to ensure robust statistical outcomes, with a goal of moving directly to a phase 3 registration trial based on positive results [21][22] Biomarker Analysis - Key biomarkers being monitored include pTAU217, pTAU243, neurogranin, GFAP, SNAP25, and NFL, which are expected to show changes correlating with clinical outcomes [29][30] - The interim analysis will assess whether PMN310 is effectively engaging its target, with expectations of biomarker levels dropping if the drug is effective [30][31] Market and Strategic Insights - The company believes that reducing ARIA liability will significantly impact prescribing habits and patient confidence, enhancing revenue potential [36][39] - ProMIS has received interest from large pharmaceutical companies, indicating a positive outlook for partnerships and acquisitions in the Alzheimer's space [37][38] Future Outlook - The company anticipates that demonstrating improved safety and efficacy could shift the risk-benefit ratio favorably, benefiting both patients and shareholders [40][41] - ProMIS is positioned to potentially validate the oligomer hypothesis in Alzheimer's treatment, which could have significant implications for the industry [37][44] Other Important Content - The discussion highlighted the shift in understanding regarding the role of amyloid beta in Alzheimer's, moving away from plaque as the primary target to focusing on toxic oligomers [6][15] - The company emphasized the importance of a well-designed clinical study to provide credible evidence for its therapeutic approach [37][44]

Financial Data and Key Metrics Changes - The company reported a total portfolio NOI growth of 21% year-over-year, with adjusted EBITDA improving by more than 30% [8][19] - Same-store occupancy increased by 90 basis points sequentially to 87.7%, reaching an average of 88% in October, marking a portfolio high [8][10] - The company achieved a year-over-year REF core increase of 4.7% [16] Business Line Data and Key Metrics Changes - The 19 communities acquired in 2024 showed a sequential improvement of 370 basis points from Q2 to Q3, with average occupancy rising from 76.3% to 83.7% over the past 12 months [9][12] - The acquisition portfolio NOI increased by $900,000 or 22% on a sequential quarter basis [17] Market Data and Key Metrics Changes - The company noted that move-outs due to deaths have returned to normal operating levels, contributing to the occupancy increase [20] - The overall labor costs, excluding benefits, increased by 70 basis points from the previous quarter due to rapid occupancy spikes [22] Company Strategy and Development Direction - The company signed a merger agreement to acquire C&L Healthcare Properties for $1.8 billion, which is expected to enhance growth and shareholder value [5][6] - The company aims to recycle lower-growth assets into higher-return acquisitions, having acquired 23 assets over the last 18 months [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving margin expansion as occupancy levels approach 90% and emphasized the importance of technology in labor management [11][40] - The company is focused on retaining and developing talent to support growth, with favorable trends in employee turnover [14] Other Important Information - The company is in compliance with all financial covenants required under its mortgages and credit facility [26] - The total transaction costs related to the merger are estimated at $75 million, with $6 million incurred in the current quarter [35] Q&A Session Summary Question: Same-store occupancy trend below industry average - Management acknowledged the occupancy improvement to 89% and noted that the increase in move-ins from internal sources has been beneficial [32][34] Question: Recurring costs related to the merger - Management confirmed that transaction costs are expected to continue as part of the merger preparation [35] Question: Long-term RevPAR versus expense trends - Management indicated that higher occupancy levels will help push rates and expand margins, with a target of achieving over 30% margins [39][41] Question: Agency labor trends in the acquired portfolio - Management reported minimal contract labor and noted improvements in permanent staffing, contributing to NOI boosts [42]

Summary of Syndax Pharmaceuticals Conference Call Company Overview - **Company**: Syndax Pharmaceuticals - **Focus**: Oncology, specifically acute leukemia and chronic graft-versus-host disease (GVHD) - **Key Products**: - **Revumenib**: First-in-class selective menin inhibitor for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) - **Niktimba**: CSF1R antibody for chronic GVHD Key Points and Arguments Product Launch and Market Opportunity - **Revumenib** targets KMT2A acute leukemia (10% of AML and ALL) and NPM1 (30-35% of AML), representing a combined market opportunity of approximately **$5 billion** [4][3] - **Niktimba** launched in February 2025 for chronic GVHD, also showing strong initial performance [4][4] Clinical Performance and Feedback - Over **750 patients** treated with Revumenib, with **one-third** progressing to transplantation [9][11] - Positive physician feedback on Revumenib's efficacy and tolerability, with expectations of **70-80%** of patients potentially returning to maintenance therapy post-transplant [13][17] - Current average duration of therapy for Revumenib is projected at **4-6 months**, expected to extend to **6-12 months** as more patients return to maintenance [24][25] Regulatory and Safety Considerations - Recent FDA update includes a black box warning for Torsades de Pointes; however, physicians remain confident in managing this risk due to existing experience with similar drugs [26][28] - Efficacy remains the primary concern for physicians, overshadowing safety warnings [30][29] Future Clinical Development - Plans to initiate frontline trials for Revumenib, focusing on both unfit and fit patient populations [38][42] - Collaboration with HOVON to expedite phase three trials, aiming for rapid enrollment and high-quality data [50][52] - Anticipated data readouts from ongoing studies, including the **MAXIMYRE** trial for Niktimba in idiopathic pulmonary fibrosis (IPF), expected in late 2026 [65][66] Financial Outlook - Niktimba has generated approximately **$46 million** in its second full quarter, with a strong adoption rate and nearly **100%** payer coverage [58][59] - Syndax holds about **$456 million** in cash, positioning the company well for future growth and profitability [68][68] Upcoming Catalysts - Key upcoming events include data presentations at ASH, potential trial readouts for Niktimba in IPF, and ongoing developments in frontline trials for Revumenib [67][68] Additional Important Insights - The company is focused on maintaining a stable expense base while driving towards profitability, leveraging its first-mover advantage in the menin inhibitor space [68][68] - The potential for Revumenib to transform treatment paradigms in AML is emphasized, particularly in combination therapies [39][40]

Financial Data and Key Metrics Changes - FreightCar America reported a revenue growth of over 42% year-over-year, totaling $160.5 million for Q3 2025, compared to $113.3 million in Q3 2024 [15] - Adjusted EBITDA reached a record $17 million, representing a 56% increase from the prior year, with an adjusted EBITDA margin of 10.6%, up from 9.6% in Q3 2024 [4][16] - Gross profit for the quarter was $24.2 million, with a gross margin of 15.1%, an increase from $16.2 million and 14.3% in the same quarter last year [15] Business Line Data and Key Metrics Changes - The company delivered 1,304 railcars in Q3 2025, up from 961 railcars in Q3 2024, reflecting higher production and deliveries [15] - The product mix improvement, including specialty new cars and conversions, contributed to the gross margin increase [16] Market Data and Key Metrics Changes - The broader railcar industry is expected to deliver under 30,000 railcars this year, significantly below the normalized rate of approximately 40,000 units [8][10] - FreightCar America maintained over 20% of the addressable market order share for new car orders, reflecting strong market positioning despite industry challenges [11] Company Strategy and Development Direction - The company is focused on enhancing operational efficiency and quality through initiatives like the TruTrack process, which integrates digital tracking and monitoring capabilities [5][12] - Strategic investments are being made in vertical integration, automation, and process control to prepare for future tank car conversions [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in capturing pent-up demand as the market normalizes, despite current subdued industry demand [8][9] - The company anticipates maintaining strong margins and positive cash generation, with a healthy backlog of 2,750 units valued at approximately $222 million [9][18] Other Important Information - The company generated $3.4 million in operating cash during the quarter, with adjusted free cash flow improving to approximately $2.2 million [17] - Capital expenditures for Q3 totaled $1.2 million, with an expectation of $4-$5 million for the full year 2025 [17][18] Q&A Session Summary Question: Guidance on CapEx and tank car conversions - Management clarified that the change in CapEx guidance was due to timing rather than scope, with preparations for tank car conversions ahead of schedule [21][22] Question: Revenue guidance and average selling price - Management explained that the revenue guidance was adjusted due to a higher proportion of conversions, which have a lower average selling price, while maintaining unit count and EBITDA guidance [25][26] Question: Demand for coal car repair - Management indicated sustained demand for coal car components and repair services, supported by the company's extensive portfolio [31] Question: Impact of government shutdown on operations - Management reported no significant disruptions from the government shutdown, noting the rail industry’s resilience to such short-term issues [32] Question: 2025 guidance and Q4 expectations - Management acknowledged that Q4 is traditionally a lower margin quarter due to annual maintenance and a shift towards more commoditized cars [39][40] Question: Addressable market for tank car retrofits - Management discussed the potential for new tank car builds following the retrofit program, estimating a couple of hundred additional cars could be added to their addressable market [41][43] Question: Industry dynamics and future order placement - Management expressed confidence in a return to normalized order levels in 2026, driven by underlying demand fundamentals [44][46]

Financial Data and Key Metrics Changes - Barrick reported strong operational and financial results for Q3 2025, achieving records in adjusted earnings per share and cash flow, with a 274% increase in free cash flow compared to Q2 [4][8] - The company ended the quarter with a net cash position, allowing for a 25% increase in the base dividend and a record cash return to shareholders [8][10] - Operating cash flow more than tripled from Q2, driven by higher gold prices, increased production volume, and lower unit costs per ounce, resulting in a 20% quarter-over-quarter increase in attributable EBITDA [8][9] Business Line Data and Key Metrics Changes - Gold production increased by 4% from Q2, primarily due to higher grades at Kibali and increased throughput at Cortez and Turquoise Ridge [6][11] - Copper production slightly declined due to a planned shutdown at Lumwana, but is expected to meet annual guidance [6][15] - North America's attributable EBITDA increased by 19% from Q2, with all sites reporting lower unit costs per ounce [11] Market Data and Key Metrics Changes - The gold price experienced a 5% increase, contributing to higher margins and a significant rise in free cash flow [6][8] - The company expects both gold and copper production to remain within their respective guidance ranges for the year, despite the impact of higher gold prices on cash costs [7][16] Company Strategy and Development Direction - The company is focusing on improving operational performance and safety, particularly in its North American gold assets, which are seen as the most significant opportunity for growth [4][17] - Barrick plans to increase exploration efforts in North America, particularly at the Fourmile project, which is considered one of the most significant gold discoveries of the century [12][18] - The company aims to maintain a strong balance sheet while returning excess cash to shareholders through dividends and buybacks [9][10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of safety and operational performance, committing to a thorough review of operations to ensure consistent delivery of value [5][16] - The company is optimistic about continued production growth in Q4, aligning with its 2025 production plan [6][16] - Management acknowledged the recent fatalities and is conducting a full investigation to enhance safety measures and culture within the organization [5][53] Other Important Information - The company has authorized a $500 million increase to its existing share repurchase program, reflecting confidence in its business [10] - Barrick's capital allocation priorities include maintaining a strong balance sheet, investing in growth, and returning excess cash to shareholders [9][10] Q&A Session Summary Question: Can you provide a framework for the operational review at Nevada Gold Mines? - The operational review aims to stabilize and improve consistency in delivery, focusing on mining efficiencies and planned maintenance to avoid unexpected issues [20][21] Question: Will the operational review include a review of medium-term guidance? - The review will help ensure predictable outcomes and will inform the budget for the next year, but no major changes are expected at this stage [28][29] Question: What is the status of the asset sales in Mali? - The focus is currently on resolving the situation regarding personnel in Mali, with asset sales on hold until that is addressed [60] Question: What changes in corporate policies can be expected under the new leadership? - The strategy remains consistent, with a heightened focus on North America and Nevada as key growth areas [82]

Financial Data and Key Metrics Changes - In Q3, the company generated revenues of $403 million, adjusted EBITDA of $41 million, and free cash flow of negative $29 million, compared to revenues of $502 million, adjusted EBITDA of $79 million, and free cash flow of $54 million in Q2 [20][34][40] - The adjusted EBITDA margin decreased to 10% from 16% in the previous quarter, reflecting operational challenges and market volatility [34][40] Business Line Data and Key Metrics Changes - Stimulation services revenues declined to $343 million in Q3 from $432 million in Q2, with adjusted EBITDA falling to $20 million from $51 million, resulting in margins of 6% compared to 12% in Q2 [39][40] - The proppant production segment generated revenues of $76 million in Q3, effectively flat from $78 million in Q2, with adjusted EBITDA of $8 million compared to $15 million in Q2, and margins decreased from 19% to 10% [40][41] - The manufacturing segment's revenues decreased to $48 million from $56 million in Q2, with adjusted EBITDA of $4 million compared to $7 million in Q2 [41] Market Data and Key Metrics Changes - The U.S. onshore completions market is experiencing cautious capital deployment, leading to increased calendar white space and operational inefficiencies [7][12] - The natural gas sector's outlook remains favorable, driven by expanding LNG export capacity and rising power demand, which are expected to support improved completions fundamentals in 2026 [12][23] Company Strategy and Development Direction - The company is prioritizing dedicated fleets paired with operators conducting more robust, less volatile programs to build a sustainable and resilient business model [7][21] - A comprehensive cost management strategy has been implemented, targeting $100 million in annualized savings by the end of Q2 2026, with specific savings identified across COGS, SG&A, and capital expenditures [9][36] - The company is focusing on maintaining financial flexibility and building a resilient platform through strategic partnerships and capital raises, including a recent equity offering that netted approximately $80 million [14][22] Management's Comments on Operating Environment and Future Outlook - Management noted that while Q3 presented challenges, there are signs of stabilization in October, with some deferred programs returning to the calendar [11][27] - The company expects global supply imbalances to normalize in 2026 as operators will need to gradually accelerate completion activity to overcome natural production decline [11][12] - Management remains optimistic about the future, citing the potential for meaningful supply-demand tightening in the hydraulic fracturing market [12][21] Other Important Information - The company has identified initial savings of $100 million at the midpoint on an annualized basis, with $35 million-$45 million driven by labor reductions already implemented [9][36] - The company is pursuing up to $200 million in incremental capital through various means, including senior secured notes and non-collateralized asset sales [22][38] Q&A Session Summary Question: How does the company approach pricing in the current market? - The company focuses on reliable, consistent programs and expects spot pricing to return to historical levels where it is typically higher than committed work [51][56] Question: What is the current portion of dedicated versus spot work? - Approximately 80% of the current work is dedicated, with expectations to shift to high 90s by 2026 [67][70] Question: Are the cost cuts considered permanent? - All cost cuts are characterized as sustainable, with a focus on maintaining the right number of employees and optimizing maintenance programs [76][79] Question: What is the outlook for the proppant production segment? - The company anticipates improved volumes and pricing in the Haynesville and South Texas regions, contributing positively to the proppant segment's performance [95] Question: What is the current capacity and attrition expected? - The company has high utilization on E fleets and dual fuel programs, with expectations for continued demand in these areas [108]

Repligen Conference Call Summary Company Overview - **Company**: Repligen (NasdaqGS:RGEN) - **Date**: November 10, 2025 - **Key Focus**: Discussion of Q3 earnings, growth strategies, and market outlook Key Points Financial Performance - **Organic Growth**: Achieved 18% organic growth, marking the fourth consecutive quarter with growth over 14% [3][4] - **Order Growth**: Orders increased by over 20%, indicating strong demand across the portfolio [3] - **Gross Margin Improvement**: Year-to-date gross margin improved by over 200 basis points year-over-year [3] Market Dynamics - **Industry Recovery**: The company noted a recovery in the equipment sector, particularly in ATF (Alternating Tangential Flow) systems, which are driving growth [10][11] - **Emerging Customer Base**: There are signs of growth in the emerging customer base, although it is still early to call it a trend [4][5] Future Outlook - **Guidance for 2026**: No formal guidance provided yet, but the company aims to grow at least five points above market growth, with potential headwinds from a discrete new modality program [6][7] - **Market Growth Rate**: Current market growth is expected to be in the high single digits (8-9%), which could position Repligen in the 11-13% growth range [7] Product Development and Strategy - **New Modalities**: The company remains optimistic about growth in new modalities, particularly in cell therapy, despite some caution around specific gene therapy programs [15][16] - **Monoclonal Antibodies (MABs)**: MABs still account for 80% of revenue, with a focus on biosimilars as a growth opportunity due to upcoming patent expirations [19][20] Operational Insights - **Onshoring Trends**: Increased activity in RFPs (Request for Proposals) related to onshoring, indicating potential new business opportunities [24][26] - **China Market**: Sales in China are beginning to recover, with expectations for growth in 2026 and beyond [29][30] Margin Expansion - **Margin Strategy**: The company aims for 100-200 basis points of margin expansion annually, focusing on top-line growth and optimizing product mix [42][46] - **Investment in Growth**: Balancing investments in growth initiatives with margin expansion is a key focus, with a commitment to long-term growth strategies [44][46] Competitive Positioning - **Product Portfolio**: Repligen's diverse product offerings allow it to compete effectively across various modalities, with a focus on innovation and customer needs [17][27] - **Resin Development**: The company is enhancing its in-house resin capabilities to reduce reliance on external partners and improve competitive positioning [39][40] Conclusion - Repligen is experiencing strong growth driven by diverse product offerings and a recovery in key markets. The company is strategically positioned to capitalize on emerging opportunities in new modalities and biosimilars while maintaining a focus on margin expansion and operational efficiency.